01/10/17. Replaces Effective Policy Dated: Amino Acid Based Elemental Formula (AABF) 09/28/15 Reference #: MP/A003 Page: 1 of 3
|
|
- Norah Burke
- 5 years ago
- Views:
Transcription
1 Reference #: MP/A003 Page: 1 of 3 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community Health Plan (PCHP) PreferredOne Insurance Company (PIC) Individual PreferredOne Insurance Company (PIC) Large Group PreferredOne Insurance Company (PIC) Small Group Please refer to the member s benefit document for specific information. To the extent there is any inconsistency between this policy and the terms of the member s benefit plan or certificate of coverage, the terms of the member s benefit plan document will govern. Benefits must be available for health care services. Health care services must be ordered by a physician, physician assistant, or nurse practitioner. Health care services must be medically necessary, applicable conservative treatments must have been tried, and the most cost-effective alternative must be requested for coverage consideration. This policy applies to PAS members only when the employer group has elected to provide benefits for the service/procedure/device. Check benefits in SPD/COC. If benefits not specifically addressed in the SPD/COC verify with the appropriate account manager the availability of benefits. PURPOSE: The intent of this policy is to provide guidelines for coverage of amino acid based elemental formulas required to sustain life. POLICY: Coverage of amino-acid based elemental formula is subject to the benefits, limitations, and exclusions in the member s benefit plan and the guidelines below. GUIDELINES: Must meet: all of I-III, and any of IV VI, as applicable I. The amino acid based elemental formula must be ordered or prescribed by a physician, physician assistant, or nurse practitioner; and II. The formula must contain 100% free amino acids as the protein source; and III. The formula is requested for one of the following metabolic or malabsorption conditions that has been diagnosed by a specialist (allergist, gastroenterologist, or pediatrician): A-G A. Amino acid, organic acid, or fatty acid metabolic and malabsorption disorders; or B. Cystic fibrosis; or C. Eosinophilic esophagitis (EE); or D. Eosinophilic gastroenteritis (EG); or E. Eosinophilic colitis; or F. Food Protein induced enterocolitis syndrome (FPIES); or G. IgE mediated allergies to food proteins documented by allergy testing.
2 Reference #: MP/A003 Page: 2 of 3 IV. PAS: Check coverage under the DME schedule of benefits V. PCHP A. Limited coverage is provided for amino-acid-based elemental formula (AABF) that are consumed orally, for members age 5 (five) years or younger. If diagnosis has not been formally made, and the child is under 1 (one) year old, but a physician is actively seeking the diagnosis, coverage may be provided for the formula for up to 90 days. B. Limited coverage is provided for amino-acid-based elemental formula, that are consumed orally, for members age 6 (six) years and older when documentation supports that such formula is medically necessary and is required to sustain good health without such formula. VI. PIC A. Individual: Limited coverage for amino-acid based elemental formulas that are consumed orally. If diagnosis has not been formally made, and the child is under 1 (one) year old, but a physician is actively seeking the diagnosis, coverage may be provided for the formula for up to 90 days. B. Large: Limited coverage is provided for orally consumed amino-acid-based elemental formula (AABF) for members age 5 (five) years or younger. If diagnosis has not been formally made, and the child is under 1 (one) year old, but a physician is actively seeking the diagnosis, coverage may be provided for the formula for up to 90 days. C. Small: Limited coverage for amino-acid based elemental formulas that are consumed orally. If diagnosis has not been formally made, and the child is under 1 (one) year old, but a physician is actively seeking the diagnosis, coverage may be provided for the formula for up to 90 days. EXCLUSION: Products purchased on the internet or OTC without a prescription DEFINITIONS: Amino-acid based elemental formulas: An amino acid-based formula, also known as an elemental formula, is a type of hypoallergenic infant formula made from individual amino acids. Amino acids are the building blocks of protein and together they form the protein requirements in formula needed for growth and development. The amino acids are in the simplest form, making it easy for the body to process and digest. EleCare, E028 Splash, Neocate, Pur Amino, Nutramigen AA LIPIL, Tolerex, and Vivonex are examples of 100% free amino acid based elemental formulas. IgE mediated gastrointestinal food allergy: An adverse reaction by the body's immune system to food that is driven by IgE. IgE antibodies specific to food molecules bind with the circulating food allergen and cause the release of immune response molecules such as cytokines. Symptoms usually occur soon after exposure to the allergen and usually cause skin symptoms. Severe cases may result in anaphylaxis. It is associated with allergic conditions such as pollen-food allergy and other oral allergies and immediate gastrointestinal hypersensitivity.
3 Reference #: MP/A003 Page: 3 of 3 FOR INTERNAL USE ONLY COVERAGE: Prior Authorization: Yes when administered orally Coverage is subject to the member s contract benefits. CODING: HCPCS B4153 Enteral formula, nutritionally complete, hydrolyzed proteins (amino acids and peptide chain), includes fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories=1 unit B4161 Enteral formula, for pediatrics, hydrolyzed/amino acids and peptide chain proteins, includes fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories=1 unit RELATED CRITERIA/POLICIES: Process Manual UR015 Use of Medical Policy and Criteria Medical Policy MP/C009 Coverage Determination Guidelines Medical Policy MP/D005 Dietary Formulas, Electrolyte Substances, or Food Products for PKU or Other Inborn Errors of Metabolism REFERENCES: 1. Minnesota Council of Health Plans 2007 Health Plan Agreement regarding Amino Acid Based Formula coverage 2. Sicherer SH. Manifestations of Food Allergy: Evaluation and Management. American Family Physician. Vol.59/No.2 (January 15, 1999). DOCUMENT HISTORY: Created Date: 09/14/10 (previously addressed under MP/E004) Reviewed Date: 08/31/11, 09/07/12, 09/06/13, 09/05/14, 09/04/15, 09/02/16 Revised Date: 09/07/11, 11/13/13, 04/20/15, 12/09/16
4 PreferredOne Community Health Plan Nondiscrimination Notice PreferredOne Community Health Plan ( PCHP ) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. PCHP does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex. PCHP: Provides free aids and services to people with disabilities to communicate effectively with us, such as: Qualified sign language interpreters Written information in other formats (large print, audio, accessible electronic formats, other formats) Provides free language services to people whose primary language is not English, such as: Qualified interpreters Information written in other languages If you need these services, contact a Grievance Specialist. If you believe that PCHP has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Grievance Specialist PreferredOne Community Health Plan PO Box Minneapolis, MN Phone: (TTY: ) Fax: customerservice@preferredone.com You can file a grievance in person or by mail, fax, or . If you need help filing a grievance, a Grievance Specialist is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at or by mail or phone at: U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C , (TDD) Complaint forms are available at Language Assistance Services NDR PCHP LV (10/16)
5 PreferredOne Insurance Company Nondiscrimination Notice PreferredOne Insurance Company ( PIC ) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. PIC does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex. PIC: Provides free aids and services to people with disabilities to communicate effectively with us, such as: Qualified sign language interpreters Written information in other formats (large print, audio, accessible electronic formats, other formats) Provides free language services to people whose primary language is not English, such as: Qualified interpreters Information written in other languages If you need these services, contact a Grievance Specialist. If you believe that PIC has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Grievance Specialist PreferredOne Insurance Company PO Box Minneapolis, MN Phone: (TTY: ) Fax: customerservice@preferredone.com You can file a grievance in person or by mail, fax, or . If you need help filing a grievance, a Grievance Specialist is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at or by mail or phone at: U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C , (TDD) Complaint forms are available at Language Assistance Services NDR PIC LV (10/16)
Department of Origin: Integrated Healthcare Services. Approved by: Chief Medical Officer Department(s) Affected: Date approved: 01/10/17
Reference #: MP/D005 Page: 1 of 3 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community Health Plan
More information01/26/17. Replaces Effective Policy Dated: Autism Spectrum Disorders in Children: Assessment 01/19/16 and Evaluation Reference #: MP/A005 Page 1 of 4
Reference #: MP/A005 Page 1 of 4 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community Health Plan
More informationPURPOSE: The intent of this policy is to provide guidelines for coverage of dental procedures under the medical benefit.
Integrated Reference #: MP/D009 Page 1 of 4 PRODUCT APPLICATION: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc.
More informationApproved by: Integrated Health Quality Management Subcommittee Effective Date: Department of Origin: Integrated Healthcare Services.
Reference #: MC/M020 Page 1 of 5 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community Health Plan
More information03/14/17. II. Initial early intensive-level behavioral and developmental therapy must have both of the following: A and B
Reference #: MC/M024 Page 1 of 6 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community Health Plan
More information09/12/17. I. Electrical Bone Growth Stimulator (invasive, semi-invasive, or non-invasive) any of the following: A-C
Reference #: MC/F021 Page: 1 of 4 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community Health Plan
More information06/13/17. A. Completed a comprehensive diabetes education program within the past two years; and
Reference #: MC/L011 Page 1 of 4 PRODUCT APPLICATION: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA
More information03/13/18. A. Symptoms lasting for greater than or equal to 12 months that have resulted to significant impairment in activities of daily living; and
Reference #: MC/I008 Page: 1 of 5 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community Health Plan
More informationFYI ONLY Generic Name. Generics available. zoledronic acid N/A
Criteria Document: Reference #: PC/A011 Page 1 of 5 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community
More informationB. To assess an individual when clinical evaluation suggests use of non-prescribed medications or illegal substances; or
Integrated Reference #: MP/D010 Page: 1 of 7 PRODUCT APPLICATION: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services,
More informationDate approved: 04/18/18. Approved by: Pharmacy and Therapeutics Quality Management Subcommittee Effective Date: Department of Origin: Pharmacy
Integrated Healthcare Services and Criteria Document: Reference #: PC/V001 Page: 1 of 9 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services,
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 12/19/17 SECTION: MEDICINE LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
MEDICAL FOODS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are
More informationCalendar Year Deductible Annual Benefit Maximum. ADA Code Covered Services Member pays. n/a Office visit $5 per visit
Blue Shield of California Dental HMO Plan Dental HMO Basic Benefit summary Effective January 1, 2018 THIS MATRIX IS INTENDED TO BE USED TO HELP YOU COMPARE COVERAGE BENEFITS AND IS A SUMMARY ONLY. THE
More informationSanta Clara Family Health Plan Cal MediConnect Plan (Medicare-Medicaid Plan) 2017 Drug List
Upcoming Changes to Santa Clara Family Health Plan Cal MediConnect Plan (Medicare-Medicaid Plan) 2017 Drug List Updated 8/1/2017 Santa Clara Family Health Plan (SCFHP) Cal MediConnect Plan (Medicare-Medicaid
More informationSmile SM Value 50/1500/No Ortho/MAC
Blue Shield of California Dental PPO Plan Smile SM Value 50/1500/No Ortho/MAC Benefit summary Effective January 1, 2018 THIS MATRIX IS INTENDED TO BE USED TO HELP YOU COMPARE COVERAGE BENEFITS AND IS A
More informationCalendar Year Deductible Annual Benefit Maximum. ADA Code Covered Services Member pays
An independent member of the Blue Shield Association A50861-SG (1/19) Dental HMO Plan Dental HMO Standard Benefit summary Effective January 1, 2019 THIS MATRIX IS INTENDED TO BE USED TO HELP YOU COMPARE
More informationSmile SM Deluxe Gold 50/1500/Ortho/U85
Blue Shield of California Dental PPO Plan Smile SM Deluxe Gold 50/1500/Ortho/U85 Benefit summary Effective January 1, 2017 THIS MATRIX IS INTENDED TO BE USED TO HELP YOU COMPARE COVERAGE BENEFITS AND IS
More information2018 Preventive Schedule
2018 Preventive Schedule Medicare-Covered Services PLAN YOUR CARE: KNOW WHAT YOU NEED AND WHEN TO GET IT Preventive or routine care helps us stay well or finds problems early, when they are easier to treat.
More informationPediatric Dental and Vision
Individual & Family Plans (IFP) and Small Business Group (SBG) Health Net of California, Inc. (Health Net) Pediatric Dental and Vision Andre Hamil Health Net When you purchase a Health Net PureCare HSP
More informationApproval of a drug under this criteria document does not ensure full coverage of the drug.
Criteria Document: Reference #: PC/A011 Page 1 of 8 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community
More informationDRUG TESTING IN PAIN MANAGEMENT AND SUBSTANCE USE DISORDER(S) TREATMENT
TREATMENT Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent
More information12/13/16. I. Liver transplantation for children and adults (initial or retransplantation) - must satisfy the following: A and B
Reference #: MC/T004 Page: 1 of 8 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community Health Plan
More informationSmile SM Plus 50/1500/Ortho/MAC
Dental PPO Plan Smile SM Plus 50/1500/Ortho/MAC Benefit summary Effective January 1, 2019 THIS MATRIX IS INTENDED TO BE USED TO HELP YOU COMPARE COVERAGE BENEFITS AND IS A SUMMARY ONLY. THE EVIDENCE OF
More informationTusculum College. Benefit Summary. $25 Copay. $25 Copay. after Deductible. 20% after Deductible 20% after Deductible
Benefit Plan Features: Annual Deductible Benefit Summary Your Cost In-Network Individual/Family $750/$1500 Annual Out-of-Pocket Maximum Individual/Family $3500/$7000 4th Quarter Carry-over Covered Services
More information12/12/17. I. Liver transplantation for children and adults (initial or retransplantation) - must satisfy the following: A and B
Reference #: MC/T004 Page: 1 of 8 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community Health Plan
More informationFECAL ANALYSIS IN THE DIAGNOSIS OF INTESTINAL DYSBIOSIS
FECAL ANALYSIS IN THE DIAGNOSIS OF INTESTINAL DYSBIOSIS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services,
More informationGENETIC TESTING FOR PREDICTING RISK OF NONFAMILIAL BREAST CANCER
Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent upon
More information06/12/18. [Note: When orthognathic surgery is not a covered benefit, it is non-covered for any diagnosis, including sleep apnea.]
Reference #: MC/B002 Page: 1 of 5 PRODUCT APPLICATION: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS)
More informationLARTRUVO (olaratumab)
LARTRUVO (olaratumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationTusculum College. Benefit Summary Option/Quote: 2. 30% after Deductible. $35 Copay. 30% after Deductible
Benefit Plan Features: Annual Deductible Effective Date: 4/1/2018 Network: S Benefit Summary Option/Quote: 2 Your Cost In-Network Individual/Family $1250/$2500 Annual Out-of-Pocket Maximum Tusculum College
More informationENDOBRONCHIAL ULTRASOUND FOR DIAGNOSIS AND STAGING OF LUNG CANCER
CANCER Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent
More informationApproved by: Integrated Health Quality Management Subcommittee Effective Date: Department of Origin: Integrated Healthcare Services.
Reference #: MC/L008 Page: 1 of 8 PRODUCT APPLICATION: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS)
More informationIMMUNE CELL FUNCTION ASSAY
IMMUNE CELL FUNCTION ASSAY Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 10/04/17 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
BAVENCIO (avelumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationDental Options 2018 BALTIMORE CITY PUBLIC SCHOOLS
Dental Options 2018 BALTIMORE CITY PUBLIC SCHOOLS Contents Important Information for 2018... 1 Dental HMO (DHMO) Dental Plan... 2 Preferred Dental PPO (DPPO) Dental Plan... 3 Summary of Dental PPO Benefits...
More informationGENETIC TESTING FOR TAMOXIFEN TREATMENT
GENETIC TESTING FOR TAMOXIFEN TREATMENT Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical
More informationRADIOFREQUENCY ABLATION OF PRIMARY OR METASTATIC LIVER TUMORS
Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent upon
More informationPANCREATIC ISLET TRANSPLANT
PANCREATIC ISLET TRANSPLANT Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationNon-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.
XOLAIR (omalizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More information03/13/18. PURPOSE: The intent of this criteria document is to ensure services are medically necessary.
Reference #: MC/C007 Page 1 of 5 PRODUCT APPLICATION: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA
More informationNUTRIENT OR NUTRITIONAL PANEL TESTING
NUTRIENT OR NUTRITIONAL PANEL TESTING Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical
More informationNon-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.
NUCALA (mepolizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More information2017 Preventive Schedule
2017 Preventive Schedule PLAN YOUR CARE: KNOW WHAT YOU NEED AND WHEN TO GET IT Preventive or routine care helps us stay well or finds problems early, when they are easier to treat. The preventive guidelines
More informationHEMATOPOIETIC CELL TRANSPLANTATION FOR EPITHELIAL OVARIAN CARCINOMA
CARCINOMA Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent
More informationOriginal Effective Date: 9/10/09
Subject: Oral and Tube Fed Enteral Nutrition Policy Number: MCR-070 *(This MCR replaces and combines MCG-070 & 071) Original Effective Date: 9/10/09 Revision Date(s): 6/29/12, 8/7/14 This MCR is no longer
More informationNon-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.
HYDROXYPROGESTERONE THERAPY Makena (hydroxyprogesterone caproate injection) Hydroxyprogesterone caproate compound Hydroxyprogesterone caproate injection with benzyl benzoate and the preservative benzyl
More information$250 (Deductible does not apply to Tier 1 and Tier 2) $500 (Deductible does not apply to Tier 1 and Tier 2)
Benefit Summary Outpatient Prescription Drug Illinois 5/50/100/250 Plan 455 Your Co-payment and/or Co-insurance is determined by the tier to which the Prescription Drug List (PDL) Management Committee
More informationALPHA1-PROTEINASE INHIBITORS
ALPHA1-PROTEINASE INHIBITORS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationPARSABIV (etelcalcetide)
PARSABIV (etelcalcetide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationNOVEL BIOMARKERS IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE
CARDIOVASCULAR DISEASE Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationGENETIC TESTING FOR KRAS, NRAS AND BRAF VARIANT ANALYSIS IN METASTATIC COLORECTAL CANCER
METASTATIC COLORECTAL CANCER Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationMOLECULAR TESTING IN THE MANAGEMENT OF PULMONARY NODULES
MOLECULAR TESTING IN THE MANAGEMENT OF PULMONARY NODULES Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services,
More informationSTELARA (ustekinumab)
STELARA (ustekinumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationORAL IMPLANT PROCEDURES
ORAL IMPLANT PROCEDURES Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationENTYVIO (vedolizumab)
ENTYVIO (vedolizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More information2018 Hearing Aids. Apply your benefit and receive two digital Level I hearing aids with $0 copay!
Quality, Affordability. Transparency. Simplicity 2018 Hearing Aids Apply your benefit and receive two digital Level I hearing aids with 0 copay! * All hearing instruments available in all sizes and styles
More informationAPOKYN (apomorphine hydrochloride)
APOKYN (apomorphine hydrochloride) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationBLINCYTO (blinatumomab)
BLINCYTO (blinatumomab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationINTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION
INTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationTYMLOS (abaloparatide)
TYMLOS (abaloparatide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationProposal to fund a number of Nutritional products (Special Foods) supplied by Nutricia
16 February 2012 Proposal to fund a number of Nutritional products (Special Foods) supplied by Nutricia PHARMAC is seeking feedback on a proposal to fund a number of nutritional products (Special Foods)
More informationMYLOTARG (gemtuzumab ozogamicin)
MYLOTARG (gemtuzumab ozogamicin) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationNon-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.
ERYTHROPOIESIS-STIMULATING AGENTS (ESAs) Epoetin alfa (Epogen, Procrit ) Darbepoetin alfa (Aranesp ) Methoxy polyethylene glycol (PEG) epoetin-beta (Mircera ) Non-Discrimination Statement and Multi-Language
More informationGATTEX (teduglutide [rdna origin])
GATTEX (teduglutide [rdna origin]) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationCIMZIA (certolizumab pegol)
CIMZIA (certolizumab pegol) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationRELISTOR (methylnaltrexone bromide) INJECTION FOR SUBCUTANEOUS USE
RELISTOR (methylnaltrexone bromide) INJECTION FOR SUBCUTANEOUS USE Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for
More informationDivision of Medical Services
Division of Medical Services Program Planning & Development P.O. Box 1437, Slot S-295 Little Rock, AR 72203-1437 501-682-8368 Fax: 501-682-2480 TO: Arkansas Medicaid Health Care Providers Hyperalimentation
More informationPERJETA (pertuzumab) FOR TREATMENT OF MALIGNANCIES
PERJETA (pertuzumab) FOR TREATMENT OF MALIGNANCIES Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationDivision of Medical Services
Division of Medical Services Program Development & Quality Assurance P.O. Box 1437, Slot S-295 Little Rock, AR 72203-1437 501-682-8368 Fax: 501-682-2480 TO: Arkansas Medicaid Health Care Providers Prosthetics
More informationPROTEOMIC TESTING FOR SYSTEMIC THERAPY IN NON-SMALL-CELL LUNG CANCER
CANCER Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent
More informationBRINEURA (cerliponase alfa)
BRINEURA (cerliponase alfa) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationBONIVA (ibandronate sodium)
BONIVA (ibandronate sodium) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationRADIOFREQUENCY ABLATION OF MISCELLANEOUS SOLID TUMORS EXCLUDING LIVER TUMORS
EXCLUDING LIVER TUMORS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationNEGATIVE PRESSURE WOUND THERAPY
NEGATIVE PRESSURE WOUND THERAPY Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationReady. Set. CAPTURE LIFE REWARDS. Earn plenty of Points. GET ACTIVE ENJOY LIVE HEALTHY REWARDS GCHJMJXEN 0916
Ready. Set. CAPTURE LIFE REWARDS Earn plenty of. GET ACTIVE GCHJMJXEN 0916 LIVE HEALTHY ENJOY REWARDS How to Register as a new user! Go to www.go365.com and click on Register now NOTE: You will need to
More informationSOMATULINE DEPOT (lanreotide acetate)
SOMATULINE DEPOT (lanreotide acetate) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical
More informationGENETIC TESTING FOR HEREDITARY HEARING LOSS
GENETIC TESTING FOR HEREDITARY HEARING LOSS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationReview/Revision Dates: 12/07, 09/2014, 09/15, 2/16
Subject: HEALTH PLAN OF SAN JOAQUIN Nutritional Supplements for Medical Conditions Department: Medical Management / Pharmacy Policy #: PH19 Effective Date: 06/01/2007 Committee/Approval Date: P&T 02/16/16
More informationArkansas Department of Health and Human Services Division of Medical Services P.O. Box 1437, Slot S-295 Little Rock, AR
Arkansas Department of Health and Human Services Division of Medical Services P.O. Box 1437, Slot S-295 Little Rock, AR 72203-1437 Fax: 501-682-2480 Internet Website: www.medicaid.state.ar.us TO: Arkansas
More informationINTRAVITREAL IMPLANTS
INTRAVITREAL IMPLANTS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationTYSABRI FOR CROHN S DISEASE
TYSABRI FOR CROHN S DISEASE Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationGENETIC TESTING FOR FANCONI ANEMIA
GENETIC TESTING FOR FANCONI ANEMIA Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationGENETIC TESTING FOR NEUROFIBROMATOSIS
GENETIC TESTING FOR NEUROFIBROMATOSIS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical
More informationTREATMENTS FOR GAUCHER DISEASE
TREATMENTS FOR GAUCHER DISEASE Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationCONTINUOUS OR INTERMITTENT GLUCOSE MONITORING IN INTERSTITIAL FLUID
FLUID Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent
More informationBALLOON OSTIAL DILATION FOR TREATMENT OF CHRONIC SINUSITIS
BALLOON OSTIAL DILATION FOR TREATMENT OF CHRONIC SINUSITIS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services,
More informationGENETIC TESTING FOR MARFAN SYNDROME, THORACIC AORTIC ANEURYSMS AND DISSECTIONS AND RELATED DISORDERS
AND DISSECTIONS AND RELATED DISORDERS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical
More informationMULTIMARKER SERUM TESTING RELATED TO OVARIAN CANCER
MULTIMARKER SERUM TESTING RELATED TO OVARIAN CANCER Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More information2018 Preventive Schedule Effective 1/1/2018
2018 Preventive Schedule Effective 1/1/2018 PLAN YOUR CARE: KNOW WHAT YOU NEED AND WHEN TO GET IT Preventive or routine care helps us stay well or finds problems early, when they are easier to treat. The
More informationHEMATOPOIETIC CELL TRANSPLANTATION FOR PRIMARY AMYLOIDOSIS
Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent upon
More informationHealthcare Common Prodecure Coding System
B4153 ENTERAL FORMULA, NUTRITIONALLY COMPLETE, HYDROLYZED PROTEINS (AMINO ACIDS AND PEPTIDE CHAIN), INCLUDES FATS, CARBOHYDRATES, VITAMINS AND MINERALS, MAY INCLUDE FIBER, ADMINISTERED THROUGH AN ENTERAL
More informationINTRACAVITARY BALLOON BRACHYTHERAPY FOR MALIGNANT AND METASTATIC BRAIN TUMORS
METASTATIC BRAIN TUMORS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationCARDIOVASCULAR RISK PANELS
CARDIOVASCULAR RISK PANELS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationVYXEOS (daunorubicin and cytarabine)
VYXEOS (daunorubicin and cytarabine) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical
More informationAUTOLOGOUS CHONDROCYTE IMPLANTATION FOR FOCAL ARTICULAR CARTILAGE LESIONS
CARTILAGE LESIONS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationELECTROMYOGRAPHY (EMG) AND NERVE CONDUCTION STUDIES (NCS)
ELECTROMYOGRAPHY (EMG) AND NERVE CONDUCTION STUDIES (NCS) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services,
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More information2017 Preventive Schedule
2017 Preventive Schedule PLAN YOUR CARE: KNOW WHAT YOU NEED AND WHEN TO GET IT Preventive or routine care helps us stay well or finds problems early, when they are easier to treat. The preventive guidelines
More information